EG-VEGF Receptor, the PROKR2, is a target for the treatment of gestational choriocarcinoma: in vitro and in vivo studies

被引：0

作者：

Alfaidy, Nadia ^{[1
]}

Traboulsi, Wael ^{[1
]}

Sergent, Frederic ^{[1
]}

Boufettal, Houssine ^{[2
]}

Slim, Rima ^{[3
]}

Bolze, Pierre-Adrien ^{[4
]}

Aboussaouira, Touria ^{[5
]}

Feige, Jean-Jacques ^{[1
]}

Benharouga, Mohamed ^{[6
]}

机构：

[1] INSERM, U1036, Biol Canc & Infect, Grenoble, France

[2] CHU Ibn Rochd, Gynecol Obstet, Casablanca, Morocco

[3] McGill Univ, Montreal, PQ, Canada

[4] CHU Lyon Sud, LCR HCL BioMerieux, Med Diagnost Discovery Dept MD3, Lyon, France

[5] Fac Med Casablanca, Canc Deprtement, Casablanca, Morocco

[6] Univ Grenoble Alpes, LCBM, UMR5249, Grenoble, France

来源：

关键词：

Choriocarcinoma; prokineticin; EG-VEGF; pregnancy; therapy;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3673

引用

页码：33 / 33

页数：1